Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

DIPNA PHARMACHEM LIMITED

Healthcare › Pharmaceuticals & Biotechnology
₹3.73
at close · 28 Oct 2026
▼ 0.07 (-1.84%)

Latest filings

  1. Two independent directors resign; new director appointed and committees reconstituted · Management Changes
  2. Board changes: one director appointed and two independent directors resign · Management Changes
  3. Two independent directors resign; new non-executive director appointed · Management Changes
All filings ↓
Ask Nexa about DIPNA PHARMACHEM LIMITED

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹199 Cr over the trailing twelve months.

Market Cap
₹10 Cr
P / E (TTM)
3.5×
EV / EBITDA
—
Div Yield
—
Growth
—·
Revenue 5y CAGR
PAT — · EBITDA —
Quality
6.9%·
ROCE (FY26)
ROE 4.2% · margin 3.9%
Leverage
0.21·
Debt / Equity · low
Net debt ₹12 Cr
Revenue FY23→FY26
1.3×▲
Revenue change
₹100 Cr → ₹129 Cr
Moves on a normal day
3.20%·
Median daily move
Last 243 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#3/158
P/B#1/163
ROCE#126/183
ROE#122/166
Debt / Equity#99/166
EBITDA margin#65/165
Revenue growth#156/161

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Negative working-capital cycle — the business is funded by its suppliers
Concerns
Nothing flagged in the filed numbers.

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from DIPNA PHARMACHEM LIMITED's filed financials and exchange disclosures

What does DIPNA PHARMACHEM LIMITED do?

DIPNA PHARMACHEM LIMITED is a Pharmaceuticals & Biotechnology company listed on BSE.

Does DIPNA PHARMACHEM LIMITED pay a dividend?

Not in the latest reported year — DIPNA PHARMACHEM LIMITED's dividend payout for FY26 was nil.

Is DIPNA PHARMACHEM LIMITED debt-free?

No. It reported borrowings of ₹13 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹12 Cr after cash. Debt stands at 0.21× equity. That is higher than 59% of its 166 Pharmaceuticals peers.

Is DIPNA PHARMACHEM LIMITED expensive compared with its peers?

On trailing P/E, DIPNA PHARMACHEM LIMITED ranks 3 of 158 in Pharmaceuticals — cheaper than 99% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.

How much does the DIPNA PHARMACHEM LIMITED share price move in a day?

On a typical session DIPNA PHARMACHEM LIMITED moves 3.20% — that is the median absolute close-to-close move across its last 243 trading days. MarketPing measures each filing's price reaction against it.

Where can I track DIPNA PHARMACHEM LIMITED's announcements?

Every NSE and BSE filing by DIPNA PHARMACHEM LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.